ACTIVE_NOT_RECRUITING

Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to assess whether 480 mg/day magnesium glycinate supplementation for 12 weeks lowers blood pressure.

Official Title

Trial of Magnesium Supplementation and Blood Pressure Reduction Among Adults With Elevated Systolic Blood Pressure

Quick Facts

Study Start:2023-01-17

Study Completion:2025-10

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05690464

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 74 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Self-report of systolic blood pressure 125-159 mmHg * Measured seated systolic blood pressure 130-159 mmHg at screening visit * Body mass index less than 40 kg/m2 * Total magnesium intake from supplements of no more than 100 mg/day * Willing to maintain current diet and supplement use patterns during the 12-week intervention period	* Measured seated diastolic blood pressure 100 mmHg or greater at screening visit * Antacid or laxative use 4 times/week or more within the past 3 months * History of cardiovascular disease (myocardial infarction, stroke, revascularization \[coronary artery bypass graft or percutaneous transluminal coronary angioplasty\], or angina pectoris) * History of invasive cancer diagnosed within the last 5 years (non-melanoma skin cancer permitted) * History of type 1 or 2 diabetes * History of renal disease * History of kidney failure * History of dialysis * History of pancreatitis * History of inflammatory bowel disease * History of hypermagnesemia * Women who are pregnant, nursing, or intend to become pregnant during the period of treatment * Plan to relocate out of Boston area within the next year * Unwillingness and/or inability to swallow 4 pills per day * Inability to provide written informed consent

Inclusion Criteria

Exclusion Criteria

* Self-report of systolic blood pressure 125-159 mmHg
* Measured seated systolic blood pressure 130-159 mmHg at screening visit
* Body mass index less than 40 kg/m2
* Total magnesium intake from supplements of no more than 100 mg/day
* Willing to maintain current diet and supplement use patterns during the 12-week intervention period

* Measured seated diastolic blood pressure 100 mmHg or greater at screening visit
* Antacid or laxative use 4 times/week or more within the past 3 months
* History of cardiovascular disease (myocardial infarction, stroke, revascularization \[coronary artery bypass graft or percutaneous transluminal coronary angioplasty\], or angina pectoris)
* History of invasive cancer diagnosed within the last 5 years (non-melanoma skin cancer permitted)
* History of type 1 or 2 diabetes
* History of renal disease
* History of kidney failure
* History of dialysis
* History of pancreatitis
* History of inflammatory bowel disease
* History of hypermagnesemia
* Women who are pregnant, nursing, or intend to become pregnant during the period of treatment
* Plan to relocate out of Boston area within the next year
* Unwillingness and/or inability to swallow 4 pills per day
* Inability to provide written informed consent

Contacts and Locations

Study Locations (Sites)

Brigham and Women's Hospital

Boston, Massachusetts, 02215

United States

Collaborators and Investigators

Sponsor: Brigham and Women's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-17

Study Completion Date2025-10

Study Record Updates

Study Start Date2023-01-17

Study Completion Date2025-10

Terms related to this study

Additional Relevant MeSH Terms

Blood Pressure